Status: Not yet recruiting
FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration
An open-label, randomized, multi-center phase III clinical study: Aim to evaluate the efficacy and safety of FCN-159 monotherapy versus the treatment by investigator's choice in patients with pediatric low-grade glioma harboring KIAA1549-BRAF fusion or BRAF V600E mutation
Participants needed: 102
Trial details
Phase: Phase 3Age: 2-18Biological sex: AllType: InterventionalSponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Updated: Jun 4, 2025Locations: 1
Eligibility criteria
Pediatric patients aged between ≥ 2 years and < 18 years; regardless of male or... [+4]
Patients who have received chemotherapy drugs or traditional Chinese medicines o... [+13]